FGF-9 蛋白, Mouse (N-His)

FGF-9 is a member of mouse heparin-binding fibroblast growth factors located on the outside of cell membranes. FGF-9 is a regulator of chondrogenesis and vascularization during bone development. FGF-9 binds to fibroblast growth factor receptors (FGFRs) to activate downstream signaling pathways, such as PI3K-AKT, RAS-MAPK and protein kinase C (PKC) pathways. FGF-9 regulates embryonic development, cell proliferation, cell differentiation and cell migration. FGF-9 plays an important role in differentiation, survival of neuronal cells and growth stimulation of glial tumors. FGF-9 Protein, Mouse (N-His) is a recombinant protein with a N-His label that consisting of 208 amino acids and is produced in E. coli^{[1][2][3][4][5]}.

成纤维生长因子是生理系统的重要生长因子，在发育、肿瘤发生、神经系统和疾病进展过程中发挥关键和多功能作用。FGF-9 蛋白 (Mouse) 参与神经元疾病，对大脑发育和功能发挥重要作用^[1]。
FGF-9 蛋白 (Mouse) 在发育早期主要局限于小鼠内脏中胚层板 (SMP) 和间皮细胞中表达，随后在小鼠内脏中胚层和稀有上皮细胞中均表达^[1]。
小鼠中 FGF-9 蛋白 (Mouse) 的缺失导致胰腺发育不全和脾功能不全^[1]。
FGF-9 蛋白 (Mouse) 通过激活 ERK/Nrf2 信号通路，减少 TBHP 诱导的软骨细胞氧化应激，并减轻小鼠骨关节炎^[2]。
FGF-9 蛋白 (Mouse) 通过激活 PD 模型细胞内 HO-1 和 γ-GCSc，上调 Nrf2 表达，增强 HD 纹状体细胞的抗氧化作用，抑制细胞凋亡 (apoptosis) 和衰老^[2]。
FGF-9 蛋白 (Mouse) 减轻小鼠中败血症引起的暴发性肝炎^[3]。
FGF-9 蛋白 (Mouse) 减轻了中性粒细胞向肝脏的浸润，并降低了 Lipopolysaccharide (LPS) (HY-D1056)/D-galactosamine (D-Gal) (HY-42682) (LPS/D-Gal) 挑战小鼠血清中促炎细胞因子的水平，如肿瘤坏死因子-α (TNF-α) 和白细胞介素-6 (IL-6)^[3]。
FGF-9 蛋白 (Mouse) 通过调节小鼠细胞增殖和透明质酸积累，促进腭生长和及时升高^[4]。

FGF-9 蛋白 (Mouse) (50,100 ng/mL) 保护软骨细胞免受 tert-丁基过氧化氢 (TBHP) (40 μM) 诱导的细胞损伤的凋亡(apoptosis)^[2]。
FGF-9 蛋白 (Mouse) (100 ng/mL) 在软骨细胞中降低 TBHP (40 μM) 诱导的氧化应激、线粒体功能障碍并激活Nrf2信号通路^[2]。

缺失 FGF-9 蛋白 (Mouse) 在功能性 FGF-9 基因敲除小鼠中会导致无脾、胰腺和胃部发育异常、肺发育不良导致的呼吸衰竭。此外，缺失 FGF-9 Protein (Mouse) 会减少功能性 FGF-9 基因敲除小鼠中早期胰腺祖细胞的数量，并且表现出上皮结构和间皮发育的缺陷。^[1]。
FGF-9 蛋白 (Mouse) (1 µg/kg，关节内注射，每天一次，持续 8 周) 改善内侧半月板不稳定（DMM）小鼠的骨关节炎（OA）^[2]。
FGF-9 蛋白 (Mouse) (0.5 或 1.5 mg/kg, 腹腔内注射，在 LPS/D-Gal 腹腔注射前后 1 小时给药）显著减轻了 LPS/D-Gal 引起的小鼠肝损伤^[3]。
FGF-9 蛋白 (Mouse) 缺陷的小鼠胚胎表现出腭部生长和提高的缺陷，细胞增殖和细胞密度增加异常，以及由于 HA 积累和细胞增殖异常损害的腭部生长和提高^[4]。
FGF-9 Protein (Mouse) 缺失在小鼠腱祖细胞中导致附着部位和腱附部的生长受损以及附着部的机械性能下降^[5]。

Measured in a cell proliferation assay using NIH/3T3 mouse fibroblast cells in the presence of 10 µg/mL of heparin. The ED₅₀ is 0.4023 ng /mL.

Mouse

E. coli

N-6*His

P54130 (A2-S208)

14180  [NCBI]

APLGEVGSYFGVQDAVPFGNVPVLPVDSPVLLSDHLGQSEAGGLPRGPAVTDLDHLKGILRRRQLYCRTGFHLEIFPNGTIQGTRKDHSRFGILEFISIAVGLVSIRGVDSGLYLGMNEKGELYGSEKLTQECVFREQFEENWYNTYSSNLYKHVDTGRRYYVALNKDGTPREGTRTKRHQKFTHFLPRPVDPDKVPELYKDILSQS

Approximately 27.91 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of 20 mM Tris, 500 mM NaCl, pH 8.5.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Patzek S, et al. Loss of Fgf9 in mice leads to pancreatic hypoplasia and asplenia. iScience. 2023 Mar 25;26(4):106500.  [Content Brief]

  [2]. Pan YN, et al. Fibroblast growth factor 9 reduces TBHP-induced oxidative stress in chondrocytes and diminishes mouse osteoarthritis by activating ERK/Nrf2 signaling pathway. Int Immunopharmacol. 2023 Jan;114:109606.  [Content Brief]

  [3]. Li A, et al. Fibroblast growth factor 9 attenuates sepsis-induced fulminant hepatitis in mice. Amino Acids. 2022 Jul;54(7):1069-1081.  [Content Brief]

  [4]. Li R, Sun Y, et al. The Fibroblast Growth Factor 9 (Fgf9) Participates in Palatogenesis by Promoting Palatal Growth and Elevation. Front Physiol. 2021 Apr 20;12:653040.  [Content Brief]

  [5]. Ganji E, et al. Targeted deletion of Fgf9 in tendon disrupts mineralization of the developing enthesis. FASEB J. 2023 Mar;37(3):e22777. doi: 10.1096/fj.202201614R. Erratum in: FASEB J. 2023 Apr;37(4):e22856.  [Content Brief]